Abstract 14365: Home Morning Systolic BP Should be Below 125mmHg in Patients With Type 2 Diabetes
Introduction: Home BP target level in patients with type 2 diabetes (T2DM) is not established.
Hypothesis: We tested the hypothesis that appropriate home morning systolic BP cutoff value is 125mmHg in stratifying cardiovascular (CV) risk in T2DM patients.
Methods: Clinic and home BP monitoring were performed in 4127 subjects and tested the different cutoff values of home morning systolic BP (MSBP) 135 mmHg and 125 mmHg. Multivariable Cox regression analyses adjusting for age, sex, BMI, history of cardiovascular events, renal dysfunction, and atrial fibrillation were used for combined CV outcomes.
Results: In Kaplan-Meyer analysis, MSBP≧135mmHg was significantly associated with the outcome in both DM and non-DM groups, whereas MSBP≧125mmHg was significantly associated with the outcome only in the DM group (Figure). In multivariable analysis, home MSBP ≧135mmHg was significantly associated with the outcome in the DM [Hazard ratio (HR) 2.45, 95%CI, 1.17-5.14, P=0.017), and the non-DM group (HR 1.79, 1.08-2.97, P=0.024). On the other hand, home BP ≧125mmHg was an independent predictor of outcome in the DM group (HR 4.35, 1.04-18.25, P=0.045), but not in the non-DM group.
Conclusions: In a large cohort sample of T2DM, the cutoff value of home MSBP would be better for 125mmHg than 135mmHg with regard to the prediction of combined CV outcomes.
Author Disclosures: K. Eguchi: None. S. Hoshide: None. K. Kario: Research Grant; Significant; Teijin Pharma Limited, OMRON HEALTHCARE Co., Ltd., FUKUDA DENSHI, Bayer Yakuhin Ltd., A &D Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED., MOCHIDA PHARMACEUTICAL CO., LTD, EA pharma, Otsuka Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan Inc., Mitsubishi Tanabe Pharma Corporation., Medtronic Japan Co., Ltd.. Honoraria; Modest; Mitsubishi Tanabe Pharma Corporation., Kyowa Hakko Kirin Co., Ltd., Bayer Yakuhin Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim Japan Inc., Sanofi K.K., TERUMO CORPORATION, Bristol-Myers K.K., Kowa Pharmaceutical Co. Ltd., SANWA KAGAKU KENKYUSHO CO.,LTD., MSD K.K., Actelion Pharmaceuticals Japan, Abott Japan, OMRON HEALTHCARE Co., Ltd., Century Medical Inc., TOA EIYO LTD., MOCHIDA PHARMACEUTICAL CO., LTD, Sumitomo Dainippon Pharma Co., Ltd.. Honoraria; Significant; Takeda Pharmaceutical Company Limited., DAIICHI SANKYO COMPANY, LIMITED., OMRON HEALTHCARE Co., Ltd..
- © 2016 by American Heart Association, Inc.